Exelixis, Inc. (LON:0IJO)

Theseus Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	164.43	217.37	262.99	501.2	647.17	319.22
Short-Term Investments	626.67	893.9	732.31	807.27	819.91	887.32
Cash & Short-Term Investments	791.1	1,111	995.3	1,308	1,467	1,207
Cash Growth	-21.05%	11.65%	-23.93%	-10.81%	21.59%	41.57%
Accounts Receivable	292.35	265.44	237.41	214.78	282.65	160.88
Other Receivables	13.9	14.9	13.1	7.3	2.9	4.5
Receivables	306.25	280.34	250.51	222.08	285.55	165.38
Inventory	23.48	22.39	17.32	33.3	27.49	20.97
Prepaid Expenses	59.93	53.58	54.83	54.91	54.63	52.51
Total Current Assets	1,181	1,468	1,318	1,619	1,835	1,445
Property, Plant & Equipment	418.21	291.96	361.98	345.44	149.15	110.39
Long-Term Investments	594.65	637.29	728.72	756.73	371.11	330.75
Goodwill	63.68	63.68	63.68	63.68	63.68	63.68
Long-Term Accounts Receivable	1.53	0.37	1.32	1.66	1.67	-
Long-Term Deferred Tax Assets	419.24	420.03	361.15	231.11	111.66	156.71
Other Long-Term Assets	-	66.79	107.56	54.11	84.22	30.4
Total Assets	2,678	2,948	2,942	3,071	2,616	2,137
Accounts Payable	25.82	38.19	33.77	32.67	24.26	23.63
Accrued Expenses	208.93	296.77	278.39	212.77	259.97	136.58
Current Portion of Leases	-	25.01	25.72	17.66	5.14	3.03
Current Unearned Revenue	2.16	2.74	5.41	7.49	7.81	1.79
Other Current Liabilities	99.2	41.06	51	53.78	40.42	39.63
Total Current Liabilities	336.11	403.77	394.28	324.36	337.59	204.66
Long-Term Leases	179.84	190.82	189.94	190.17	51.27	49.09
Long-Term Unearned Revenue	2.62	3.39	5.52	6.58	8.74	3.76
Other Long-Term Liabilities	125.97	105.5	88.7	61.95	8.02	0.72
Total Liabilities	644.55	703.49	678.45	583.06	405.62	258.22
Common Stock	0.27	0.28	0.3	0.32	0.32	0.31
Additional Paid-In Capital	2,251	2,344	2,441	2,537	2,428	2,322
Retained Earnings	-219.54	-98.65	-173.35	-34.23	-216.51	-447.57
Comprehensive Income & Other	1.35	-1.35	-3.75	-14.52	-0.76	4.48
Shareholders' Equity	2,034	2,244	2,264	2,488	2,211	1,879
Total Liabilities & Equity	2,678	2,948	2,942	3,071	2,616	2,137
Total Debt	179.84	215.83	215.66	207.83	56.41	52.11
Net Cash (Debt)	1,206	1,533	1,508	1,101	1,411	1,154
Net Cash Growth	49.99%	1.62%	37.04%	-21.98%	22.20%	44.03%
Net Cash Per Share	4.17	5.18	4.69	3.39	4.38	3.63
Filing Date Shares Outstanding	269.2	279.88	303.19	324.09	319.45	311.99
Total Common Shares Outstanding	270.13	281.73	302.79	323.95	318.84	311.63
Working Capital	844.65	1,064	923.68	1,294	1,497	1,241
Book Value Per Share	7.53	7.97	7.48	7.68	6.93	6.03
Tangible Book Value	1,970	2,181	2,200	2,425	2,147	1,815
Tangible Book Value Per Share	7.29	7.74	7.27	7.48	6.73	5.83
Machinery	-	108.97	95.62	83.23	54.4	45.01
Construction In Progress	-	2.88	24.47	4.93	16.87	16.36
Leasehold Improvements	-	108.28	89.04	83.33	73.59	40.69

Source: S&P Global Market Intelligence. Standard template. Financial Sources.